FindTrial
Sign In

Efficacy of Narrow Band Ultraviolet B Phototherapy in Reducing Pruritus in Chronic Kidney Disease-associated Pruritus (CKD-aP) in Fitzpatrick Skin Types III-V: an Open Label, Randomised Controlled Trial

Efficacy of Narrow Band Ultraviolet B Phototherapy in Reducing Pruritus in Chronic Kidney Disease-associated Pruritus (CKD-aP) in Fitzpatrick Skin Types III-V: an Open Label, Randomised Controlled Trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260613001
Enrollment
48
Registered
2026-06-13
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study aimed to evaluate the efficacy of narrowband ultraviolet B (NB-UVB) phototherapy combined with standard medical treatment compared with standard medical treatment alone in reducing pruritus severity and improving quality of life in patients with CKD-associated pruritus. Pruritus

Interventions

Procedure, Narrow-Band UVB Light Treatment, emollient and antihistamine,Emollient and antihistamine
Experimental Device,Active Comparator Drug
Group A,Group B

Sponsors

DERMATOLOGY UNIT, HOSPITAL AL SULTAN ABDULLAH, UNIVERSTI TEKNOLOGI MARA, MALAYSIA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older. 2. Diagnosis of CKD stage 4 or higher (estimated glomerular filtration rate less than 30 mL/min/1.73m2). 3. Clinical diagnosis of CKD-aP (defined as chronic itch secondary to declining renal function in the absence of primary dermatological conditions). 4. Ability to comprehend instructions and answer questions in either English or Malay. 5. Provision of written informed consent.

Exclusion criteria

Exclusion criteria: 1. Active primary dermatological conditions that could explain pruritus generally or regionally 2. Other known systemic diseases causing pruritus, including hepatitis B, hepatitis C, HIV infection, or thyroid disorders 3. Pregnancy or breastfeeding 4. Active and unstable photo-dermatoses and contraindicated to phototherapy

Design outcomes

Primary

MeasureTime frame
change in itchiness intensity Baseline, Week 3, Week 6 (treatment endpoint), and Week 8 (2 week post treatment) VAS- Visual analogue scale,multidimensional itch scale Baseline, Week 3, Week 6 (treatment endpoint), and Week 8 (2 week post treatment) 5D-IS- 5-Dimensional Itch Scale—

Secondary

MeasureTime frame
quality of life Baseline, Week 3, Week 6 (treatment endpoint), and Week 8 (2 week post treatment) DLQI- Dermatology Life Quality Index—

Countries

Malaysia

Contacts

Public ContactMOHD SHAZWAN SHAHRUDIN

UNIVERSITI TEKNOLOGI MARA, MALAYSIA

shazwanshahrudin@gmail.com60132746745

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026